![腾博会官网·[中国]-诚信为本,专业服务!
制药英文站](http://zhengzhoujiaobanji.com/userfiles/images/banner/sinologo.png)
Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 20252025.06.18
-
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TDI01 SUSPENSION (“ROCK2 INHIBITOR”) INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE2025.06.16
-
VOLUNTARY ANNOUNCEMENT - THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP2025.06.13
-
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 10 JUNE 20252025.06.10
-
VOLUNTARY ANNOUNCEMENT2025.06.10
-
AMENDED AND RESTATED ARTICLES OF ASSOCIATION2025.06.10
-
VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE2025.06.09
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PRESENTED AT 2025 ASCO ANNUAL MEETING2025.06.05